Investors

RXi Pharmaceuticals to Present at BioPharm America's 10th Annual International Partnering Conference

Sep 18, 2017

MARLBOROUGH, Mass., Sept. 18, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that Dr. James Cardia, Director of Business Development and Intellectual Property at RXi Pharmaceuticals, will present at BioPharm America's 10th Annual International Partnering Conference being held in Boston, MA. This life sciences partnering conference draws innovative leaders across biotech, finance, and pharma providing access to cutting-edge technologies and new potential therapies and cures through industry presentations, networking sessions and pre-scheduled partnering meetings.  This meeting will be held September 26-27, 2017 at the Sheraton Boston Hotel.

Dr. Cardia will present a corporate overview that includes the Company's proprietary self-delivering RNA (sd-rxRNA®) therapeutic platform and the ongoing research and clinical programs in cell-based immunotherapy, dermatology, and ophthalmology.

Date:Tuesday, September 26
Time: 10:45 AM ET
Room: Republic A, Level 2
Cell and Gene Therapies category

The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com approximately 1 hour following the presentation.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology, and cell-based immunotherapy.  RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies.  For additional information, visit the Company's website, www.rxipharma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact

RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

 

View original content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-biopharm-americas-10th-annual-international-partnering-conference-300520979.html

SOURCE RXi Pharmaceuticals Corporation

Investors